SG10202011023YA - Dna monoclonal antibodies targeting il-6 and cd126 - Google Patents

Dna monoclonal antibodies targeting il-6 and cd126

Info

Publication number
SG10202011023YA
SG10202011023YA SG10202011023YA SG10202011023YA SG10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA
Authority
SG
Singapore
Prior art keywords
seq
nucleotide sequence
antibody
nucleic acid
composition
Prior art date
Application number
SG10202011023YA
Other languages
English (en)
Inventor
David Weiner
Original Assignee
Univ Pennsylvania
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst filed Critical Univ Pennsylvania
Publication of SG10202011023YA publication Critical patent/SG10202011023YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10202011023YA 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126 SG10202011023YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05

Publications (1)

Publication Number Publication Date
SG10202011023YA true SG10202011023YA (en) 2020-12-30

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011023YA SG10202011023YA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126
SG11201809786TA SG11201809786TA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809786TA SG11201809786TA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (enExample)
EP (1) EP3452106A4 (enExample)
JP (3) JP7311113B2 (enExample)
KR (3) KR20250011241A (enExample)
CN (1) CN109789224A (enExample)
AU (2) AU2017261292B2 (enExample)
BR (1) BR112018072697A2 (enExample)
CA (1) CA3023089A1 (enExample)
EA (1) EA201892524A1 (enExample)
MX (2) MX2018013523A (enExample)
SG (2) SG10202011023YA (enExample)
WO (1) WO2017192933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534941A4 (en) * 2016-11-07 2020-07-08 The Wistar Institute Of Anatomy And Biology CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST LYME DISEASE
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2632628C (en) * 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
WO2008019061A2 (en) * 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
JP2011520898A (ja) * 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8992908B2 (en) * 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
EP2931318A4 (en) * 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Also Published As

Publication number Publication date
AU2017261292A1 (en) 2018-12-20
JP2019518074A (ja) 2019-06-27
JP2023086734A (ja) 2023-06-22
KR20190031439A (ko) 2019-03-26
JP7311113B2 (ja) 2023-07-19
BR112018072697A2 (pt) 2019-02-19
WO2017192933A1 (en) 2017-11-09
KR20250011241A (ko) 2025-01-21
EP3452106A4 (en) 2020-01-08
JP2025147175A (ja) 2025-10-06
AU2024203109A1 (en) 2024-05-30
CN109789224A (zh) 2019-05-21
AU2017261292B2 (en) 2024-06-06
US20190192692A1 (en) 2019-06-27
AU2024203109B2 (en) 2026-05-21
EP3452106A1 (en) 2019-03-13
MX2025009846A (es) 2025-09-02
KR20230058733A (ko) 2023-05-03
EA201892524A1 (ru) 2019-04-30
SG11201809786TA (en) 2018-12-28
CA3023089A1 (en) 2017-11-09
MX2018013523A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
IL275547A (en) Antigen-binding proteins target co-antigens
ZA202001285B (en) Antigen-binding proteins targeting shared antigens
ZA201902533B (en) Anti-pd-l1 antibodies and variants
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
ZA201707138B (en) Anti-ceacam6 antibodies and uses thereof
PL3426686T3 (pl) Humanizowane przeciwciała anty-pacap i ich zastosowanie
IL256086A (en) Anti-her2 antibodies and methods of use
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
LT3353212T (lt) Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
SG10201913500TA (en) Anti-ctla-4 antibodies and methods of use thereof
HUE073610T2 (hu) Terápiás ellenanyagok és alkalmazásaik
SG11201705475QA (en) Fcrn antibodies and methods of use thereof
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
IL254951A0 (en) Monoclonal antibodies of influenza of human origin and methods of using them
GB201506409D0 (en) Humanized anti-axl antibodies and their conjugates
SG11201708624YA (en) Therapeutic antibodies and uses thereof
IL257323A (en) New antibodies against human gpvi and their uses
IL267271A (en) Antibodies against il-5
SG10202011021XA (en) Dna monoclonal antibodies targeting influenza virus
EP3452106A4 (en) MONOCLONAL DNA ANTIBODIES AGAINST IL-6 AND CD126
IL266059A (en) Anti-rankl antibodies and their uses
GB201511196D0 (en) Monoclonal antibodies
GB201621446D0 (en) IL-11 antibodies